About Outcomes-Based Contracting
Life sciences manufacturers are facing heightened pressure from the government and other entities to lower the cost of drugs while improving patient outcomes.
In an effort to shift from price-per-volume to high-value care, manufacturers are being tasked with bringing treatments to market with outcomes-based, risk-sharing agreements.
CBI’s 3rd Annual Outcomes-Based Contracting Summit delivers key insights into the process of outlining, structuring and negotiating successful performance and value-based contracts.
This conference also provides an excellent platform for manufacturers, payers and providers to discuss the challenges and successes regarding government price reporting, value optimization and price alignment with health outcomes data.
The University of Texas Medical School